top of page
Improving your
Understanding of Theranostics
Theranostics is a cutting-edge approach in modern medicine that combines diagnostic and therapeutic capabilities into a single integrated platform. By utilising molecular imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), theranostics enables clinicians to accurately diagnose diseases and assess their molecular characteristics. In addition to diagnosis, theranostics also involves the targeted delivery of therapeutic agents, such as radioactive isotopes or nanoparticles, to specific disease sites identified during imaging. This personalised treatment approach allows for precise and effective therapy tailored to individual patients, leading to improved outcomes and reduced side effects.
Theranostics represents a promising avenue for advancing precision medicine and transforming the way we diagnose and treat diseases.
Oncothera Advocacy Joins the Australian Patient Advocacy Alliance (APAA)
Oncothera Advocacy is proud to announce that we have joined the Australian Patient Advocacy Alliance (APAA) as a member organisation, marking another important milestone in our commitment to supporting patients and advancing the future of theranostics in Australia.
What is Theranostics? A New Era of Precision Cancer Care
The word "theranostics" combines two concepts: therapy and diagnostics. Traditionally, diagnosing a disease and treating it have been separate processes. Theranostics brings these two elements together by using the same biological target to both identify cancer cells and deliver treatment directly to them. In simple terms, theranostics allows clinicians to locate cancer with remarkable precision and then use that information to guide a targeted treatment strategy.
What to Expect from Theranostics Treatment
While every person's diagnosis and treatment plan is different, theranostics typically follows a structured pathway that combines advanced medical imaging with targeted treatment. Your treating specialists will guide you through each step based on your individual circumstances.
How Theranostics is Transforming Thyroid Cancer Treatment
Thyroid cancer develops when abnormal cells grow uncontrollably within the thyroid – a small, butterfly-shaped gland located at the base of the neck. The thyroid produces hormones that help regulate many important functions in the body, including metabolism, heart rate and body temperature.
How Theranostics is Transforming Neuroendocrine Cancer Treatment
Neuroendocrine tumours, commonly known as NETs, are a diverse group of uncommon cancers that develop from neuroendocrine cells. These specialised cells are found throughout the body and share characteristics of both nerve cells and hormone-producing endocrine cells. NETs can behave very differently.
How Theranostics is Transforming Prostate Cancer Treatment
Prostate cancer is one of the most advanced applications of theranostics today. PSMA-targeted imaging and therapy have significantly changed how advanced prostate cancer is diagnosed and treated.
The Role of Theranostics in Modern Oncology Practice
Advances in molecular imaging, biomarker identification and targeted radionuclide therapies are enabling more personalised treatment approaches that can better characterise disease and inform therapeutic decision-making. Theranostics sits at the centre of this evolution.
The National Actinium-225 Survey: Understanding the Future of Actinium-Based Therapies
Oncothera Advocacy and the Radiopharma Initiative are calling on clinicians, researchers, institutions, CROs, regulators, and industry stakeholders to help shape the future of Actinium-based therapies. Your input and insights will help inform future advocacy, research priorities, infrastructure planning, and clinical readiness across the theranostics ecosystem. If you work in nuclear medicine, oncology, radiopharma, research, policy, and other related areas.
Precision Medicine in Action: Driving NSW’s Theranostics Research & Clinical Future
An educational symposium hosted by Oncothera Advocacy, with the support of government and commercial partners. 21st March 2026, University of Sydney Oncothera Advocacy was proud to host Precision Medicine in Action: Driving NSW’s Theranostics Research & Clinical Future this past weekend at the University of Sydney, welcoming more than 65 attendees from across clinical, research, policy and industry sectors. The strong turnout and sustained engagement throughout the day refle
World Theranostics Day: Advancing Awareness, Empowering Patients
On World Theranostics Day, Oncothera Advocacy highlights the power of precision medicine to transform cancer care. Partnering with the Oncidium Foundation, we’re combining global momentum with a strong Australian, patient-first focus—raising awareness, improving access, and ensuring more patients benefit from theranostics.
Why Neutral Advocacy Matters in Emerging Therapies
Neutral advocacy means speaking up for what’s right – not what’s commercially convenient.
It means putting patients, evidence and equity at the centre, rather than representing a single manufacturer, company, or commercial agenda.
Championing Patient Access to Theranostics in Australia: About Us
We’re excited to share the launch of the Oncothera Advocacy “About Us” flyer, a concise introduction to our mission: making theranostics...
Patients at the Heart: How Oncothera is Advancing Theranostics in Australia
Oncothera: A Patient-Centric Approach to Theranostics Patient-Centric Approach to Theranostics At Oncothera, we believe that patients should be at the core of every decision in the theranostics landscape. As a registered charity, our mission is to advocate for better patient access, foster collaboration among key industry players, and drive awareness for the life-changing potential of theranostic treatments. Through education, debate, and strategic partnerships, we aim to cre
World Theranostics Day: Recognising Oncothera’s Mission and the People Behind It
World Theranostics Day: 31st March 2025 On this #WorldTheranosticsDay, we take a moment to reflect on the growing impact of theranostics in transforming cancer care. Today is also an opportunity to acknowledge the dedicated individuals leading Oncothera, a not-for-profit registered charity founded in early 2024. Our Mission: Expanding Access to Theranostics in Australia Oncothera was established with a clear and urgent purpose—to improve access for Australian patients to cutt
Pioneering a New Frontier in Cancer Treatment: The Promise of Theranostics
Through strategic advocacy, collaboration, and a commitment to patient care, Oncothera aims to make Theranostics a standard of care, ultimat
The Growing Field of Theranostics
The field of Theranostics is rapidly gaining momentum, revolutionising the way we diagnose and treat cancer. This innovative approach...
Radiant Creations: The Art of Isotope Manufacturing
In Australia theranostic products are currently manufactured two ways: Hospital manufacture - isotopes are imported from ANSTO or...
Radiant Revelations: Exploring Isotopes - Alpha, Beta, Gamma, and Beyond
Different isotopes are used to provide the therapeutic component of a theranostic treatment. Isotopes are divided into the following...
Glowing Opportunities: Exploring Radioisotope Clinical Applications
Currently the two largest indications for theranostics is for treatment of advanced metastatic prostate cancer and for treating...
Prostate Precision: Unveiling the Theranostic Evidence
To date most of the evidence for theranostic treatments has revolved around the prostate cancer indication.
More from our social media
bottom of page